Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.


Options:
A: Arm Label: Arm A: Nivolumab + Gemcitabine + Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Gemcitabine, Drug: Cisplatin | Arm Label: Arm B: Nivolumab + Pemetrexed + Cisplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Cisplatin, Drug: Pemetrexed | Arm Label: Arm C: Nivolumab + Paclitaxel + Carboplatin; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Arm D: Nivolumab + Bevacizumab maintenance; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Bevacizumab | Arm Label: Arm E: Nivolumab + Erlotinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Erlotinib | Arm Label: Arm F: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm G: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm H: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm J: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm K: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm L: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm M: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm O: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm P: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm Q: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm R: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm S: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin, Arm B: Nivolumab + Pemetrexed + Cisplatin, Arm C: Nivolumab + Paclitaxel + Carboplatin, Arm D: Nivolumab + Bevacizumab maintenance, Arm E: Nivolumab + Erlotinib, Arm F: Nivolumab, Arm G: Nivolumab + Ipilimumab, Arm H: Nivolumab + Ipilimumab, Arm I: Nivolumab + Ipilimumab, Arm J: Nivolumab + Ipilimumab, Arm K: Nivolumab, Arm L: Nivolumab, Arm M: Nivolumab, Arm N: Nivolumab + Ipilimumab, Arm O: Nivolumab + Ipilimumab, Arm P: Nivolumab + Ipilimumab, Arm Q: Nivolumab + Ipilimumab, Arm R: Nivolumab + Ipilimumab, Arm S: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm A: Nivolumab + Gemcitabine + Cisplatin, Arm B: Nivolumab + Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm B: Nivolumab + Pemetrexed + Cisplatin | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm D: Nivolumab + Bevacizumab maintenance | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Arm E: Nivolumab + Erlotinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm G: Nivolumab + Ipilimumab, Arm H: Nivolumab + Ipilimumab, Arm I: Nivolumab + Ipilimumab, Arm J: Nivolumab + Ipilimumab, Arm N: Nivolumab + Ipilimumab, Arm O: Nivolumab + Ipilimumab, Arm P: Nivolumab + Ipilimumab, Arm Q: Nivolumab + Ipilimumab, Arm R: Nivolumab + Ipilimumab, Arm S: Nivolumab + Ipilimumab
B: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Arm Label: Paclitaxel+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Gemcitabine+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine | Arm Label: Gemcitabine+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel+Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Gemcitabine+Carboplatin, Paclitaxel+Carboplatin, Pemetrexed+Carboplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Paclitaxel+Carboplatin, Pemetrexed+Carboplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine+Cisplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine+Carboplatin, Gemcitabine+Cisplatin
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: D